Literature DB >> 26942628

Reply to Dr. Peter Paradiso.

Daniel M Musher1,2,3, Maria B Rodriguez-Barradas1,2.   

Abstract

Year:  2016        PMID： 26942628      PMCID： PMC4964824          DOI： 10.1080/21645515.2016.1149672

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  6 in total

1.  Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.

Authors:  Daniel M Musher; Maria B Rodriguez-Barradas
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

3.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Authors:  Lisa A Jackson; Alejandra Gurtman; Kathryn Rice; Karlis Pauksens; Richard N Greenberg; Thomas R Jones; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma
Journal:  Vaccine       Date:  2013-05-18       Impact factor: 3.641

4.  Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

Authors:  Nick J Andrews; Pauline A Waight; Robert C George; Mary P E Slack; Elizabeth Miller
Journal:  Vaccine       Date:  2012-09-18       Impact factor: 3.641

5.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

6.  Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.

Authors:  Daniel M Musher; Ingrid L Roig; Guillermo Cazares; Charles E Stager; Nancy Logan; Hossam Safar
Journal:  J Infect       Date:  2013-03-19       Impact factor: 6.072
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.